Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1996-8-26
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0021-9738
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
98
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-2
|
pubmed:dateRevised |
2008-11-20
|
pubmed:meshHeading |
pubmed-meshheading:8690779-Cytotoxicity, Immunologic,
pubmed-meshheading:8690779-Humans,
pubmed-meshheading:8690779-Killer Cells, Natural,
pubmed-meshheading:8690779-Macrophage-1 Antigen,
pubmed-meshheading:8690779-Neoplasms,
pubmed-meshheading:8690779-Neutrophils,
pubmed-meshheading:8690779-Polysaccharides
|
pubmed:year |
1996
|
pubmed:articleTitle |
The continuing saga of complement receptor type 3 (CR3)
|
pubmed:publicationType |
Editorial,
Comment
|